SCHEMBL2876608

SCHEMBL2876608

CC(CNC(=O)OC(C)(C)C)c1ccc(-c2ccc(F)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 3/20 0.43
CTSK P43235 3/20 0.43
GRM2 Q14416 1/20 0.41
SYK P43405 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
GRIA4 P48058 1/20 0.39
CYP17A1 P05093 2/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
PCSK9 Q8NBP7 1/20 0.38
SCN9A Q15858 1/20 0.38
AAK1 Q2M2I8 1/20 0.38
MMP13 P45452 1/20 0.38
SDCBP O00560 1/20 0.38
SDC2 P34741 1/20 0.38
FFAR1 O14842 1/20 0.37
POLB P06746 2/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5878194 0.84 GRIA4 (0.56) CTSSCTSKSYKCTSLCTSB
SCHEMBL12817338 0.83 ACHE (0.44) CTSSCTSKSYKGRIA4MAPT
SCHEMBL6788864 0.82 GRIA4 (0.55) CTSSCTSKSYKCTSLCTSB
SCHEMBL5877996 0.82 GRIA4 (0.55) CTSSCTSKSYKCTSLCTSB
SCHEMBL5877829 0.82 GRIA4 (0.55) CTSSCTSKSYKCTSLCTSB
SCHEMBL2434610 0.82 CTSS (0.45) CTSSCTSKGRM2SYKPOLB
SCHEMBL16363856 0.82 CTSS (0.45) CTSSCTSKGRM2SYKPOLB
SCHEMBL255676 0.82 AAK1 (0.50) CTSSCTSKSYKMAPTPCSK9
SCHEMBL5877530 0.82 AAK1 (0.50) CTSSCTSKSYKMAPTPCSK9
SCHEMBL165863 0.82 SYK (0.41) CTSSCTSKSYKGRIA4PCSK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662845-B2 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 ASTRAZENECA AB (SE) 2010-02-16 US disclosed
US-7354940-B2 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2008-04-08 US disclosed
EP-1542977-B1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. ASTRAZENECA AB (SE) 2006-12-20 EP disclosed
US-20060276524-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 ASTRAZENECA AB, A SWEDEN CORPORATION 2006-12-07 US disclosed
US-20050245586-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2005-11-03 US disclosed
EP-1542977-A1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. AstraZeneca AB (SE) 2005-06-22 EP disclosed
WO-2004020415-A1 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. ASTRAZENECA AB (SE) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276524-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 MMP12, MMP13, MMP9 CTSS 207/4885CTSK 389/4885GRM2 2997/4885
US-20050245586-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 MMP12, PDE12, MMP13 CTSS 191/4885CTSK 405/4885GRM2 3284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.